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Abstract
The TNF-receptor superfamily member CD30 is expressed on normal and malignant lymphocytes, including anaplastic large
cell lymphoma (ALCL) cells. CD30 transmits multiple effects, including activation of NF-kB signaling, cell proliferation,
growth arrest and apoptosis. How CD30 generates these pleiotropic effects is currently unknown. Herein we describe ALCL
cells expressing truncated forms of the CD30 intracellular domain that allowed us to identify the key regions responsible for
transmitting its biological effects in lymphocytes. The first region (CD30519–537) activated both the alternative and canonical
NF-kB pathways as detected by p100 and IkBa degradation, IKKb-dependent transcription of both IkBa and the cyclin-
dependent kinase inhibitor p21WAF1/CIP1 and induction of cell cycle arrest. In contrast, the second region of CD30 (CD30538–
595) induced some aspects of canonical NF-kB activation, including transcription of IkBa, but failed to activate the alternative
NF-kB pathway or drive p21WAF1/CIP1-mediated cell-cycle arrest. Direct comparison of canonical NF-kB activation by the two
motifs revealed 4-fold greater p65 nuclear translocation following CD30519–537 engagement. These data reveal that
independent regions of the CD30 cytoplasmic tail regulate the magnitude and type of NF-kB activation and additionally
identify a short motif necessary for CD30-driven growth arrest signals in ALCL cells.
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Introduction
CD30 (TNFRSF8) is a member of the tumour necrosis factor
superfamily (TNFRSF), a group defined by the presence of
homologous cysteine-rich domains in the extracellular region and
which is intimately involved with immune regulation. CD30
exhibits limited expression in health, being predominantly
expressed on activated T and B cells. In cancer CD30 is most
consistently expressed by Reed-Sternberg cells of Hodgkins
lymphoma and a group of neoplasms known as anaplastic large
cell lymphoma (ALCL), making it a relatively specific target for
immunotherapy [1,2]. Receptor cross-linking of CD30 activates
pleiotropic signals depending on the cell type and agents used.
Thus, stimulation of thymocytes, mature T cells, or T-cell
hybridomas through CD30 induces apoptosis and cell death [3–
6] although enhanced proliferation/survival of T cells has also
been reported [7]. Similarly, stimulation of ALCL cells via CD30
drives low levels of apoptosis, NF-kB activation, anti-apoptotic
signals mediated via the p38 MAPK pathway and growth arrest
through the cyclin-dependent kinase inhibitor p21WAF1/CIP1 [7–
12]. In contrast Hodgkins lymphoma cell lines fail to undergo
CD30-induced anti-proliferative effects probably due to high
constitutive NF-kB activation [8,9], and instead show a further
increase in proliferation in some [7,11], though not all [8], studies.
It is unclear how CD30 is able to activate such a diversity of signals
and how this is regulated.
TNFRSF signaling to NF-kB is largely mediated via members
of the TNF receptor-associated factor (TRAF) family. Studies in
transfected cell lines have shown that TRAFs 1, 2, 3 and 5 interact
directly with CD30 via two TRAF-binding sites; residues 561–573
(CD30561–573) which bind TRAFs 1, 2, 3 and 5, and residues 578–
586 (CD30578–586) with specificity for TRAFs 1 and 2 [13–16]. In
addition, an upstream region of the CD30 cytoplasmic domain
may also be involved in transmitting CD30 signals in human
embryonic kidney (HEK)293 cell transfectants [16,17].
Signaling pathways leading to NF-kB activation converge at the
level of the IKK complex which facilitates degradation of IkB-
family proteins resulting in release and preferential nuclear
localisation of the previously IkB-bound NF-kB transcription
factor. NF-kB exists as a homo- or hetero-dimer comprised from 5
sub-units (p65 (also called RelA), RelB, cRel, p100/p52 and p105/
p50) defined by the presence of the Rel homology domain, which
enables DNA binding and interaction with IkB [18]. Canonical
NF-kB activation utilises an IKKb-containing complex to drive
phosphorylation and degradation of the classical IkB proteins
IkBa, IkBb and IkBe resulting in predominantly release of the
p65/p50 dimer [18]. A subset of the TNFRSF, including CD30,
CD40 and BAFFR, additionally activate the alternative NF-kB
pathway [19]. For CD40 and BAFFR this is achieved subsequent
to TRAF2, cIAP-1 and cIAP-2 dependent degradation of TRAF3
[20]. In resting cells TRAF3 targets the IKK kinase NIK for
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proteasomal degradation; thus, receptor driven TRAF3 degrada-
tion allows NIK stabilisation and subsequent NIK-mediated
phosphorylation/activation of homodimeric IKKa [20,21]. Acti-
vated IKKa facilitates degradation of the C-terminal region of
p100 (which acts as an IkB protein) to release the p52 fragment
and allow nuclear entry of RelB/p52, the prototypical alternative
NF-kB isoform. While the canonical NF-kB pathway is associated
with proliferative and pro-survival signaling, non-canonical NF-kB
activation regulates lymphogenesis during development. However,
some evidence additionally points to a role for elements of the non-
canonical NF-kB pathway in enhancing canonical NF-kB
activation [22–24].
Previous reports which sought to identify the cytoplasmic
regions that transmit CD30 signaling utilised ectopic expression of
constitutively active (ligand-independent) CD30 variants in
HEK293 cells, a cell type in which CD30 expression has never
been observed [13,15–17]. Consequently, the role of the various
cytoplasmic sub-domains of CD30 in mediating its specific effects
in haematopoietic cells, including the induction of cell cycle arrest
remains unknown. To gain insight into how CD30 induces
pleiotropic signals in haematopoietic cells, we generated ALCL
cell lines expressing chimeric forms of CD30 incorporating
truncated versions of its intracellular domain fused to the
extracellular region of the related TNFR superfamily member 4-
1BB (TNFRSF9). By studying the effects of 4-1BBL stimulation on
these cells, we report that the intracellular domain of CD30
comprises at least two distinct functional regions with independent
and disparate signaling activity.
Materials and Methods
Cell Lines and Plasmids
ALCL cell lines Karpas-299 (from DSMZ, Germany, and
authenticated by multiplex PCR, cytogenetics and mycoplasma
testing) and Michel (kindly provided by Prof. W. Murphy,
University of Nevada, NV, USA and described in reference
[25]) and subsequently authenticated as mycoplasma negative
(Endosafe-PTS, Charles River, U.K.) and CD30- and ALK-
rearrangement positive (FISH kindly performed by Dr. F. Ross,
Wessex Regional Genetics Laboratory, Salisbury, U.K,) were
maintained as described [10,12]. Cells were expanded, aliquoted
and frozen and maintained for less than 6 months in culture. For
chimeric receptors, RNA was extracted (RNeasy; Qiagen,
Crawley, U.K.) and cDNA synthesised (SuperscriptH III First
Strand Kit; Invitrogen, Paisley, U.K.) from Con-A treated murine
splenocytes (m4-1BB) and Karpas-299 cells (hCD30). Sequence
encoding the extracellular and transmembrane domains of 4-1BB
flanked by BglII and XhoI sites was amplified using primers BglII4-
1BBF; TTTAGATCTCATTTCGCCATGGGAAACAAC and 4-
1BBtaillessXhoIR; TTTCTCGAGTTAGATCCATTTGAGCA-
CAGA, cloned (Zero-Blunt TOPO PCR Cloning Kit; Invitrogen)
and ligated into pMSCV2.2 to generate pTL. For pFL, over-
lapping sequences were spliced encoding firstly, the extracellular
and transmembrane regions of m4-1BB and a region of the
hCD30 cytoplasmic tail and secondly, a region of m4-1BB and the
entire hCD30 cytoplasmic region, amplified by PCR using
forward (BglII4-1BBF and CTGTTCTCTGTGCTCCACCG-
GAGGGCCTGC) and reverse (GCAGGCCCTCCGGTGGAG-
CACAGAGAACAG and CD30XhoIR; TTTCTCGAGT-
CACTTTCCAGAGGCAGC) primers, and m4-1BB and
hCD30 templates, respectively. Plasmids p519, pD1 and pD1D2
were constructed using pFL as template, BglII4-1BBF as forward
primer and TTTCTCGAGTCAGATGTAGATTTTCTC (p519);
TTTCTCGAGTCACCGGCCCTCCGGCAG (pD1) and
TTTCTCGAGTCAGACATCGCTGCAGCT (pD1D2) as reverse
primers. For pD2D3, sequence encoding m4-1BB extracellular
and transmembrane domains, hCD30 cytoplasmic tail to residue
519 and a short sequence from D2 of hCD30 were amplified from
pFL using primers BglII4-1BBF and TGGCCCCGCCAGGCC-
GATGTAGATTTTCTC and spliced with sequence encoding
hCD30 residues 515–519, 538–595 and XhoI restriction site,
similarly synthesised using primers GAGAAAATCTA-
CATCGGCCTGGCGGGGCCA and CD30XhoIR. All products
were inserted into pMSCV2.2 upstream of internal ribosomal
entry sequence (IRES) and GFP and inserts sequenced.
Retroviral Transduction and Flow Cytometry
Plasmid DNA and pCL-Ampho (Imgenex, San Diego, CA,
U.S.A.) were transfected into amphotropic Phoenix cells (LGC
Standards, Middlesex, U.K.) using calcium phosphate (with
25 mM chloroquine) or Effectene Transfection Reagent (Qiagen).
Virus was collected at 48 hours, spin-infected onto ALCL cell lines
and GFP+ cells sorted using a FACsAria. Surface 4-1BB expression
was confirmed by flow cytometry (FACSCalibur; Becton Dick-
inson, Oxford, U.K.) using rat anti-mouse 4-1BB (LOB12.3) or rat
anti-mouse OX40 control (OX86; both in house) and allophyco-
cyanin-conjugated anti-rat antibody (Jackson ImmunoResearch
Laboratories, Suffolk, U.K.).
Ligands and Blocking Reagents
Soluble recombinant CD30L and 4-1BBL immunoglobulin
fusion proteins have been described [12,26]. ALCL cells were
stimulated with 10 mg/ml CD30L, 4-1BBL, human immunoglob-
ulin or CD70 [27] (controls) or titrated doses of 4-1BBL. For
blockade of signaling pathways, 10 mM TPCA-1 (2-[(aminocarbo-
nyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), UO126,
SB203580 or SP600125 (or dimethyl-sulfoxide as a control) were
used in the presence of 25 mM pan-caspase inhibitor zVAD-FMK
(all Calbiochem, Darmstadt, Germany).
Cell Cycle and Growth Arrest Analysis
Cell cycle analysis [12] and [3H]-thymidine uptake assays [28]
were performed as described. Data are expressed as either mean
% [3H]-thymidine uptake of triplicates relative to untreated cells
(set at 100%; Figure 1), or as % growth inhibition normalised to
that induced by CD30L (set at 100%; Figure 2).
Immunoblot
For immunoblotting, 0.5–16106 cells were lysed in protein
solubilization buffer (PSB) [12], reduced, denatured and resolved
on 10% SDS-PAGE gel. Cytoplasmic and nuclear lysates were
prepared by differential detergent fractionation using published
methods [29]. Proteins were transferred to Immobilon-P mem-
branes (Millipore, Billerica, MA, U.S.A.), incubated with anti-
bodies against IkBa (C-15), p100/p52 (C-5), actin (C-11; all Santa
Cruz Biotechnology, Santa Cruz, CA, U.S.A.), p21WAF1/CIP1
(DCS60), phospho-IkBa (5A5), p65, p105/p50 or lamin A/C
(4C11; all Cell Signaling Technology, Danvers, MA, U.S.A.) and
visualised with HRP-conjugated anti-rabbit, anti-mouse (both GE
Healthcare, Bucks, U.K.) or anti-goat (Santa Cruz Biotechnology)
secondary antibodies using Supersignal West Pico Chemilumines-
cent Substrate (Thermo Fisher Scientific, Loughborough, U.K.).
Quantitative PCR
IkBa and p21waf1 transcripts from stimulated or control ALCL
cells were quantitated using quantitative reverse-transcription-
PCR (qRT-PCR) as described [30] using TaqMan gene expres-
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sion assays Hs00153283m1 (IkBa) and Hs00355782m1 (p21waf1)
and HPRT (TaqMan assay Hs02800695m1; all Applied Biosys-
tems, CA, U.S.A.) as a reference gene. Fold expression relative to
untreated cells was determined using the DDCT method.
Results
CD30L Induces Growth Arrest in ALCL Cells
We and others have previously reported that exposure of the
ALCL cell line Karpas-299 to either membrane-expressed or
soluble CD30 ligand (CD30L, CD153) induces cell cycle arrest
[10,12]. To investigate whether CD30L induces growth arrest in
another ALCL cell line, we incubated the CD30-expressing ALCL
cell line, Michel with CD30L. Pronounced growth arrest at the
G0G1 stage was repeatedly observed (Figure 1A) with greater than
70% reduction in cell proliferation in longer-term cultures
(Figure 1B).
Upregulation of the Cell Cycle Inhibitor p21WAF1/CIP1 and
Growth Arrest is Initiated through CD30519–537 in ALCL
Cells
CD30-induced growth arrest in Karpas-299 cells correlates with
increasing expression of the cyclin dependent kinase inhibitor
p21WAF1/CIP1 [8,10], a known target of NF-kB [10,31]. Three
regions of the CD30 cytoplasmic tail independently induce NF-kB
activation in HEK293 cells [13–17]. To determine if these regions
upregulate p21WAF1/CIP1 and thereby induce growth arrest in
ALCL cells, we constructed a panel of retroviral plasmids
encoding chimeric receptors which incorporate the extracellular
and transmembrane domains of murine 4-1BB alone or in frame
with full-length or truncated segments of the human CD30
cytoplasmic tail to enable m4-1BBL-induced CD30 signaling
(Figure 2A). Receptors were designed based on domains 1, 2 and 3
(henceforth D1, D2 and D3) described by Horie et. al. (1998) [17].
Domains D2 and D3 each incorporate one of the two previously
defined TRAF-binding sites while D1 represents a non-TRAF
binding region [14,16,17]. In the present study we have reduced
D1 from CD30500–538 to CD30519–537 based on data indicating an
absence of NF-kB activity from CD30500–519 [17]. Retroviral
constructs were stably introduced into Karpas-299 cells and
similar surface expression of the chimeric transgenes was
confirmed by detection of murine 4-1BB protein (Figure 2B),
and mRNA for each of the receptor variants by RT-PCR (data not
shown).
Cells expressing a chimeric receptor incorporating the full-
length CD30 intracellular tail (pFL; Figure 2C) upregulated
p21WAF1/CIP1 protein by 6 hours following 4-1BBL stimulation; in
contrast little p21WAF1/CIP1 was induced by cells expressing the
minimal p519 receptor as anticipated. Unexpectedly, p21WAF1/
CIP1 expression was greater when signaling emanated from D1
compared with D2D3 (Figure 2C; compare centre and far right
panels). In addition, the D1D2-containing receptor stimulated
slightly increased p21WAF1/CIP1 expression compared with D1
(Figure 2C, compare central and fourth panels). Comparable
increases in p21WAF1/CIP1 protein were detected in all cell lines
after incubation with CD30L, confirming that p519 and pD2D3-
expressing cells retained competency for endogenous signaling via
CD30. Together these data reveal that the majority of p21WAF1/
CIP1 protein synthesis is initiated by signals from the D1 domain,
with a small contribution from D2.
To determine whether differential expression of p21WAF1/CIP1
correlates with induction of tumour growth arrest, cell lines were
incubated alone, with irrelevant ligand (control), 4-1BBL or
CD30L and [3H]-thymidine uptake used as a measure of cell
proliferation (Figure 2D). As expected, substantial growth in-
hibition was observed in Karpas-299 cells expressing pFL but not
pTL or p519 after 4-1BBL incubation (means and SEM across 3
experiments; 88.7% +/24.1%, 12.3% +/22.8% and 6.5% +/
24.1% inhibition respectively). Notably the division of 4-1BBL-
stimulated pD1 and pD1D2 expressors was also inhibited (means
of 74.6% +/25.8% and 89.2+/24.6% inhibition respectively
across 3 experiments) in line with the high levels of p21WAF1/CIP1
protein induced in these cells (Figure 2C). In contrast, 4-1BBL-
stimulated Karpas-299 cells that expressed pD2D3 showed
relatively little growth arrest (mean of 36.3% +/27.2% inhibition
across 3 experiments), significantly lower than that induced by
signals through either pD1 or pD1D2 again reflecting the low
expression of p21WAF1/CIP1 protein by activated pD2D3-expres-
sing cells compared with pD1 and pD1D2 expressors (Figure 2C).
To determine if signals from CD30 D1 drive growth arrest in
other ALCL cells, Michel cells were similarly transduced with pFL,
p519, pD1 or pD1D2 plasmids and comparable expression of
surface 4-1BB confirmed by flow cytometry (Figure S1). Again,
pFL, pD1D2 and pD1, but not p519, transductants showed 4-
1BBL-induced growth inhibition (Figure 2E). Flow cytometric
DNA content analysis confirmed that reduced [3H]-thymidine
uptake after 4-1BBL-stimulation was due to growth inhibition
rather than apoptosis (Figure S2 and data not shown). Together
these data reveal a novel role for the D1 region (residues 519–537)
of CD30 in driving upregulation of p21WAF1/CIP1 and retardation
of ALCL cell growth.
Distinct Cytoplasmic Regions of CD30 are Required for
Activation of the Alternative and Canonical NF-kB
Pathways
Activation of NF-kB in certain cell types, including the ALCL
cell line Karpas-299, is known to upregulate expression of
p21WAF1/CIP1 [10]. To ascertain whether increased expression of
p21WAF1/CIP1 downstream of D1 correlates with activation of NF-
kB, the kinetics of IkBa phosphorylation and degradation were
determined in 4-1BBL-stimulated Karpas-299 cell lines expressing
the various chimeric receptors (Figure 3A). In all cells, except those
transduced with p519, expression of phosphorylated IkBa peaked
within 5–10 minutes of 4-1BBL incubation and IkBa was
Figure 1. CD30L triggers growth arrest in two ALCL cell lines.
Karpas-299 (K-299) or Michel cells were incubated alone, with control
(human IgG) or CD30L for (A) 24 hours and DNA content determined by
propidium iodide staining; numbers indicate the percentage of cells in
G0/G1 (left) or S-phase (right), or (B) 72 hours with [
3H]-thymidine added
for the final 16 hours. Bar graphs show the mean (+/2SEM) percentage
of [3H]-thymidine uptake from triplicate wells in control or CD30L-
stimulated cells; data are expressed as a percentage of [3H]-thymidine-
uptake relative to untreated cells (normalised to 100%) and are
representative of at least 3 independent experiments.
doi:10.1371/journal.pone.0045244.g001
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degraded and undetectable by 15 minutes showing that CD30 D1
and D2D3 independently activate the canonical NF-kB signaling
pathway in ALCL cells. To characterise whether the alternative
NF-kB pathway is engaged differentially by D1, D2 and/or D3,
cells were stimulated with 4-1BBL or CD30L for 24 hours prior to
detection of the p100/p52 NF-kB component (Figure 3B). In-
cubation of all transduced cell lines with CD30L resulted in
degradation of p100 to the NF-kB subunit p52 as expected from
previous reports [10,32]. However after 4-1BBL incubation, p52
accumulation was only observed in cells expressing chimeric
receptors incorporating D1 (i.e. cells transduced with pFL, pD1 or
pD1D2). Indeed cells expressing a chimeric receptor encoding the
entire cytoplasmic domain of human CD30 but lacking only D1
(pD2D3), failed to engage the alternative NF-kB pathway after
incubation with 4-1BBL (Figure 3B), despite being fully competent
for canonical NF-kB activation (Figure 3A). Michel cells trans-
duced with pD1 similarly showed p52 accumulation following
incubation with 4-1BBL (data not shown). These data demonstrate
that activation of the canonical pathway can be instigated
independently via either D1 or D2D3 whilst D1 is solely
responsible for transmitting the signals required for activation of
the alternative NF-kB pathway.
Previously, upregulation of p21WAF1/CIP1 by the full length
intracellular domain of CD30 was shown to be dependent on
the canonical NF-kB pathway [10]. Figure 4A shows that the
presence of the D1, but not D2D3, region was required for
expression of the p21WAF1/CIP1 transcript, consistent with
induction of the p21WAF1/CIP1 protein by this domain. In
contrast, signals downstream of either D1 or D2D3 were
sufficient to induce expression of IkBa, a known target of the
canonical NF-kB pathway (Figure 4B). To investigate whether
the canonical NF-kB pathway downstream of the D1 region is
required for upregulation of p21WAF1/CIP1, we incubated cells
with (TPCA-1), a selective inhibitor of IKKb [33]. TPCA-1
completely ablated CD30 D1-induced upregulation of mRNA
encoding p21WAF1/CIP1 and IkBa (Figure 4C and 4D re-
spectively) confirming that transcription of both genes is
dependent on the canonical NF-kB pathway. Of note, TPCA-
1 did not prevent stimulation-induced degradation of p100 to
p52 (Figure 4E), showing that activation of the alternative NF-
kB pathway was not inhibited. As expected de novo synthesis of
p100 was prevented by TPCA-1, confirming that p100 is itself
a target of the canonical NF-kB pathway [34]. Finally, CD30
D1-induced p21WAF1/CIP1 expression was not suppressed by
inhibitors of the JNK, ERK or p38 MAPK pathways
(Figure 4C). Thus, while p21WAF1/CIP1 and IkBa transcription
both require activation of the canonical NF-kB pathway which
is triggered independently from both CD30 D1 and D2D3, only
D1 is fully competent for p21WAF1/CIP1 transcription.
The CD30 D1 Region Drives Increased Nuclear
Accumulation of NF-kB p65 when Compared to D2D3
The NFKB1A gene which encodes IkBa incorporates 6 NF-
kB-binding sites in its proximal promoter region, is exquisitely
sensitive to the presence of nuclear NF-kB and is induced
rapidly after receptor activation [35,36]. In contrast, the
CDKN1A gene encoding p21WAF1/CIP1 contains 2 kB-binding
sites [31,37] and is induced relatively late after receptor
triggering. Given that transcription of late genes requires
persistent nuclear NF-kB [35,36], we hypothesised that greater
accrual of nuclear p65 is required to drive transcription of
p21WAF1/CIP1 and that this level is attained after signaling
through D1 but not D2D3. To illustrate the differential
sensitivity of IkBa and p21WAF1/CIP1 transcription following
receptor signaling we compared expression of these two genes in
cells stimulated with different concentrations of ligand. Figure 5A
shows that when compared to IkBa transcription, initiation of
p21WAF1/CIP1 transcription from D1 required at least a 10-fold
higher concentration of the agonist ligand. This suggested that
transcription of p21WAF1/CIP1 requires activation of a greater
fraction of receptors when compared to transcription of IkBa,
consistent with the notion that expression of p21WAF1/CIP1
requires increased nuclear concentrations of NF-kB. In
Figure 5B we demonstrate that signals mediated through D1
caused cytoplasmic egress of p65 within 1 hour whereas D2D3-
Figure 2. Signals from CD30 D1 drive increased expression of p21WAF1/CIP1 and growth arrest in ALCL cells. (A) Schematic
representation of all retroviral constructs showing the position of domains (D1, D2 and D3) of hCD30 downstream of m4-1BB extracellular and
transmembrane (TM) domains. Numbers indicate CD30 residues relative to their position in full-length hCD30. (B) Karpas-299 cells were stably
transduced with the constructs indicated and surface expression of m4-1BB detected by flow cytometry (open histograms); filled histograms
represent staining with isotype control. (C) Karpas-299 transductants were stimulated for 6 or 24 hours with 4-1BBL or CD30L or left untreated for 24
hours and p21WAF1/CIP1 detected by immunoblot; actin is shown as a loading control. Blots are representative of two independent experiments. To
determine the role of CD30 domains in triggering growth arrest, Karpas-299 (D) or Michel (E) cells transduced with the plasmids indicated, were
stimulated for 72 hours and [3H]-thymidine uptake determined as a measure of cell cycling. Data are normalised to maximum growth inhibition (that
induced by CD30L, set at 100%) and to minimum inhibition (medium alone; 0%) to show relative % inhibition induced by CD30L, 4-1BBL or control
(CD70). Data in panels D and E are pooled from 3 of 3 (D) or 2 of 2 (E) experiments and show means and SEM. One-way ANOVA was performed on 4-
1BBL-stimulated data sets across all experiments and was significant for Karpas-299 (p,0.0001) and Michel (p,0.018) cells. Statistical analyses using
the Students two-tailed t-test were therefore performed comparing the means of individual groups; *p,0.05, **p,0.005, n.s. p.0.05.
doi:10.1371/journal.pone.0045244.g002
Figure 3. CD30 D1 is necessary and sufficient for activation of
the alternative NF-kB pathway. (A) Karpas-299 transductants were
incubated alone (0) or with 4-1BBL for 5, 10, 15, 20 or 30 mins and
expression of phospho-IkBa (upper panels) or total IkBa (central panels)
determined by immunoblot. (B) Karpas-299 transductants were in-
cubated for 24 hours alone or in the presence of 4-1BBL or CD30L; p100
and its degradation product p52 were detected by immunoblot. Blots
in (A) and (B) are representative of 2 independent experiments and
actin expression (lower panels) is shown as a loading control.
doi:10.1371/journal.pone.0045244.g003
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induced signaling was more protracted with decreased cytoplas-
mic p65 protein only detectable from 2–3 hours. In line with
this kinetic profile, nuclear p65 accumulation was greater
following D1 signaling compared with D2D3 (Figure 5C and
D). The expression of nuclear p50 was similar from D1 and
D2D3-expressors (Figure 5E). These data support our conten-
tion that NF-kB activation from D2D3 is sufficient only for
IkBa transcription whereas increased nuclear p65 from D1
additionally drives expression of p21WAF1/CIP1.
Discussion
We and others have reported previously that CD30 signaling in
ALCL cells drives upregulation of the cyclin-dependent kinase
inhibitor p21WAF1/CIP1 leading to growth arrest at the G0/G1
stage [8,10,12]. The data presented herein define a short region of
the CD30 intracellular tail (D1; CD30519–537) that is responsible
for mediating this effect. This same domain additionally activates
the canonical NF-kB pathway and is necessary and sufficient for
activation of the alternative NF-kB pathway. An additional
membrane distal domain (D2D3; CD30538–595) independently
activated only the canonical NF-kB pathway, but failed to induce
upregulation of p21WAF1/CIP1. Our finding that D1 mediates
substantial downstream signals stands in contrast with previous
reports which together ascribe the majority of NF-kB activation
from CD30 to CD30538–595 [14,15]. However, two reports have
described variable levels of NF-kB activation from domains similar
to D1 (CD30519–538 [17] and CD30524–531 [16]) following
transfection of HEK293 cells, albeit without addressing which
NF-kB pathway is being activated or whether this region is
required for induction of p21WAF1/CIP1. Additionally, ectopic
expression of CD30 in HEK293 cells results in ligand-independent
signaling [17] and thus may not be relevant to physiological
activation of CD30. Our data extend previous findings by
Figure 4. Differential regulation of NF-kB-dependent genes by
CD30 D1 and D2D3. Karpas-299 cells stably transduced with pD1
(closed circles) or pD2D3 (open squares) were incubated with 4-1BBL,
and p21WAF1/CIP1 (A) and IkBa (B) transcripts quantitated over time by
qRT-PCR. Data show fold increase over untreated cells. (C and D)
Karpas-299 pD1 transductants were incubated for 30 minutes with
inhibitors of IKK-b (TPCA-1), ERK (UO126), p38 (SB203580; SB), JNK
(SP600125; SP) or with an equal volume of DMSO (2), prior to addition
of 4-1BBL where specified. After a further 7 hours p21WAF1/CIP1 (C) and
IkBa (D) transcripts were quantitated by qRT-PCR. (E) In parallel whole
cell lysates were assayed by immunoblot for p100/p52 and actin. Data
are pooled from 2 (A and D) or 3 (B and C) experiments or are
representative of 2 experiments (E). Graphs express the mean (+/
2SEM)-fold increase in transcript expression over untreated (A and B) or
DMSO-only treated (C and D) cells; *p,0.05 by two tailed Students t-
test. The short arrow indicates a non-specific band above p52 (E).
doi:10.1371/journal.pone.0045244.g004
Figure 5. CD30 D1 triggers greater nuclear p65 accumulation
than D2D3. (A) Karpas-299 cells stably transduced with pD1 were
incubated with titrated doses of 4-1BBL for 5 hours and p21WAF1/CIP1
(open squares) and IkBa (closed circles) transcripts quantitated by qRT-
PCR. Data represent the percentage fold-increase in expression relative
to untreated (0%) and 10 mg/ml treated (100%) cells. (B, C, D and E)
Karpas-299 cells stably transduced with pD1 or pD2D3 were incubated
with 4-1BBL for the times indicated and cytoplasmic (B) or nuclear (C, D
and E) fractions assayed by immunoblot for p65 (B, C and D), p50 (E)
and actin and lamin as loading controls. D shows the fold-increase in
nuclear p65 from pD1- (closed circles) and pD2D3- (open squares)
expressing cells relative to time zero and normalised to lamin,
calculated by densitometry and were obtained from a separate
experiment to that shown in (C).
doi:10.1371/journal.pone.0045244.g005
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demonstrating that signals through CD30 D1 alone are sufficient
to drive canonical and alternative NF-kB activation in cells that
endogenously express CD30 and importantly that D1 signaling
induces transcription of p21WAF1/CIP1 and impairs tumour cell
division dependent on the canonical NF-kB pathway.
Our finding that independent functions can be ascribed to
different regions of the CD30 cytoplasmic tail is reminiscent of
aspects of CD40 signaling wherein alternative NF-kB activation
requires a TRAF2/3 binding region but is independent of
a TRAF6 binding domain [38]; conversely CD40-dependent
polarization of macrophages towards an inflammatory phenotype
requires TRAF6, but not TRAFs 2 or 3 [39]. For CD30, NF-kB
signals emanating from D2D3 are likely mediated via TRAFs 2
and 5 [15]. However, in light of reports that TRAF proteins bind
only to the D2D3 domain, it is unclear how D1 is able to engage
downstream signaling pathways [13–16]. Duckett et. al. (1997)
previously proposed that CD30410–531, which incorporates all but
7 residues of D1, may represent a death domain (DD)-like region
analogous to those found in the cytoplasmic domains of other
members of the TNFRSF e.g. TNFR1, Fas and DR3 [16].
Recruitment of TRADD, RIP1 and TRAF2 to the DD of TNFR1
or DR3 drives NF-kB activation with TRADD acting as a bridge
for TRAF2 binding [40–43]. Whether D1 binds to DD-containing
proteins or other protein(s) not currently associated with classical
TNFRSF signaling pathways remains to be determined. The
requirement for TRAF family members further downstream of D1
is also controversial; one report documents complete abrogation of
NF-kB signaling from CD30500–538 by dominant negative versions
of TRAFs 2 or 5 [17] whereas others have shown no deleterious
effects of dominant negative TRAFs 1, 2 or 3 on NF-kB activation
arising from CD30410–531 (incorporating D1 but not D2D3)
signaling in HEK293 cells [16]. In our hands, Karpas-299 cells
stably transduced with dominant negative TRAF2 continue to
undergo growth arrest and activate the alternative NF-kB pathway
after CD30L incubation (data not shown) lending support for
a TRAF-independent mode of signal transduction from D1 in
ALCL cells.
An obvious question arising from our results concerns how both
D1 and D2D3 domains can induce canonical NF-kB activation
and transcription from NFKB1A, yet only D1 is fully competent for
driving transcription of the NF-kB-dependent CDKN1A gene. The
NFKB1A gene is an ‘early gene’ reflecting the rapid kinetics of its
transcription by NF-kB, and as such is upregulated rapidly in
response to low levels of receptor agonist in a digital (on/off)
manner. In contrast genes exhibiting a slower kinetic of expression
such as p21WAF1/CIP1, respond with a more analogue profile,
being more sensitive to both initial dose and stimulus persistence
[36]. Our data are entirely in keeping with these findings and
indicate that the lower initial nuclear concentration and short-
lived nuclear p65 seen following D2D3 signaling is probably
sufficient only for IkBa transcription whereas D1-induced p65
accumulation is of sufficient magnitude to additionally allow for
p21WAF1/CIP1 upregulation and growth arrest. The question that
then arises is why should p65 nuclear import be greater after D1
engagement compared with D2D3? CD30 interacts with the aryl
hydrocarbon nuclear translocator (ARNT) via the D2D3 region
which is thought to be part of a negative feedback pathway that
interferes with recruitment of TRAFs to the D2D3 region, thus
suppressing NF-kB activation downstream of CD30 [44]. Because
D1 does not interact directly with either TRAFs or ARNT, the
signals that activate NF-kB emanating from D1 are less likely to be
subject to negative regulation by ARNT, providing a potential
explanation for the higher levels of NF-kB activation downstream
of D1.
In addition it is plausible that concurrent activation of the
alternative NF-kB pathway by D1 may augment the magnitude of
canonical NF-kB signaling. Indeed several aspects of the
alternative NF-kB pathway can act in this manner. For example,
loss of TRAF3, which occurs within 30 minutes of CD40 or
BAFFR stimulation and which is necessary for NIK accumulation
[20,21], additionally permits increased p65/p50 nuclear import
and transcription of NF-kB target genes after TNF-a stimulation
[23]. In addition, knock-down of NIK abrogates not only CD27-
driven p100 processing to p52 but also IkBa degradation and
nuclear p65 accumulation [24] while NIK stabilisation results in
loss of IkBa [22] indicating a positive role for NIK in canonical
NF-kB activation. Furthermore, as well as targeting p100 for
proteolysis, activated IKKa drives phosphorylation of both IkBa
and IKKb, the latter serving to further enhance IkBa degradation
[45,46]. Finally, dimers of p100 have been shown to retain p65/
p50 complexes in the cytosol of resting cells thereby inhibiting
their DNA binding activity. On activation of the alternative NF-
kB pathway p100 is processed to p52 thereby releasing the bound
p65/p50 transcription factor and driving canonical NF-kB
activation [47]. A mathematical model which takes this additional
role of p100 into account predicts that activation of the canonical
pathway alone will drive a high magnitude but transient RelA/p50
nuclear signal which returns to base level by 2 hours, whereas
a receptor which triggers only the alternative pathway induces
a low but gradual increase in canonical NF-kB activity over time
[47]. This finding fits with our results in which D2D3 activates
transcription of the sensitive NFKB1A gene only, whereas D1
promotes enhanced nuclear accumulation of p65 favouring
additional p21WAF1/CIP1 transcription. Although activation of
the alternative NF-kB pathway is considered prolonged compared
with the canonical pathway, p100 degradation can be detected as
early as 20 minutes after CD27 stimulation confirming that loss of
p100 early during alternative NF-kB activation might influence
the magnitude of simultaneous canonical NF-kB activation
[24,47].
Our data also show that blockade of IKKb inhibits the
transcription of p21WAF1/CIP1, but not the processing of p100
downstream of D1, confirming the canonical NF-kB dependency
of p21WAF1/CIP1 transcription. A previous report has similarly
shown RelA (p65), but not p100, to be an important driver of
p21WAF1/CIP1 transcription downstream of full length CD30 in
ALCL cells [10]. Interestingly, depletion of p100 slightly increased
p21WAF1/CIP1 expression in that report [10] thereby ruling out an
essential role for p52 in driving p21WAF1/CIP1 transcription from
D1 and instead providing support for an IkB-type function of p100
as described above. Furthermore, p100 and p65 associate in
resting Karpas-299 cells [32], further suggestive of a potential
inhibitory role of p100 on canonical NF-kB activation from CD30
in these cells.
Finally, our finding that distinct functions of CD30 are
attributed to discrete cytoplasmic regions suggests a mechanism
to explain how CD30 engagement leads to different cellular
outcomes. Specifically, we propose that alternative utilization of
these cytoplasmic motifs in different cell types, or as a result of
CD30 engagement by different agonists, is responsible for the
multiple and often opposing roles of CD30 [3–9].
Supporting Information
Figure S1 Expression of 4-1BB on the surface of trans-
duced Michel cells. Michel ALCL cells were stably retrovirally
transduced with the plasmids indicated and surface expression of
4-1BB confirmed by flow cytometry. Plots show staining with
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isotype control (filled histograms) or with anti-4-1BB (open
histograms) antibody.
(TIF)
Figure S2 Signaling through CD30 induces minimal
apoptosis. Karpas-299 cells retrovirally transduced with the
receptors indicated were incubated alone or with 4-1BBL for 24
hours prior to analysis of DNA content by propidium iodide
staining. Numbers indicate the percentage of cells undergoing
apoptosis (left) or in S-phase (right).
(TIF)
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